Sanofi Pasteur Set To Ship Japan’s First Foreign Hib Vaccine
This article was originally published in PharmAsia News
Executive Summary
The head of France-based Sanofi Pasteur said Japan's first foreign-made vaccine for hemophilus influenza type B is expected to be on the market by December. The drug is notable for being the first vaccine licensed by a multinational drug maker to be sold in Japan. Sanofi President Wayne Pisano said strict Japanese approval requirements had delayed the vaccine being allowed there even as it was available in other countries. The infectious disease affects children under 5 with meningitis and pneumonia. Japan expects to receive about 500,000 doses of the vaccine each year. The company make
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.